Industry Urges Caution Over Japan HTA Plans
This article was originally published in PharmAsia News
Japan may have decided to dip an exploratory toe in the waters of health technology assessment, but the research-based pharma industry is continuing to voice early caution over potential shortcomings in methodology and expertise, and to stress the need for a holistic approach.
You may also be interested in...
Japan has reported big rises in drug costs covered by its national health insurance scheme, driven in large part by hepatitis C and cancer, adding weight to ongoing discussions of possible new cost containment measures.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.